Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Tata Consultancy Services - Q4FY21 Result Update - ICICI Securities

Posted On: 2021-04-15 01:55:35 (Time Zone: UTC)


Downgrade cycle ahead?

Reported growth and margins were in-line with our / consensus estimates. As we reach the fag end of the recovery leg, organic growth (2.6% QoQ, CC, our estimate) reverted more or less towards pre-Covid baseline levels for March quarter. This corroborates our argument that industry growth is unlikely to witness a meaningful acceleration (vs pre-Covid) over medium term as is expected by the street. On expected lines, deal win TCV (US$9.2bn) remained healthy and the management reiterated double-digit growth outlook for FY22. Given the good pace of vaccination in core markets like US / UK, potential resumption of costs related to marketing events / onsite travel (in H2FY22) is a key thing to watch out for. As we rebase our exchange rate estimates (now INR / US$ = 75 / 76 for FY22 / FY23E), FY22E EPS witnesses ~5% upgrade even as FY23E EPS remains largely stable. We downgrade the stock to HOLD (from ADD earlier) with an unchanged TP of Rs3,350 (implying 30x FY23E EPS). Tactically, in the context of 2nd wave in India, TCS should command relative investor interest given (1) low / no disruption to IT and (2) perception of the stock as a cash proxy during heavy market volatility.

- In-line revenue growth and margins. Revenue growth of 4.2% QoQ (CC) is in-line with expectations. Of this, we estimate ~1.6% contribution from captive takeover deals which ramped up during this quarter. It should be noted that organic revenue growth of 2.6% QoQ (CC, our estimate) was more or less in-line with pre-Covid growth rates for March quarter. Outside BFSI (includes inorganic), verticals like retail (+4% QoQ, CC), manufacturing (+3.9% QoQ, CC) and Healthcare (+3.8% QoQ, CC) have delivered good sequential growth. While the former two were aided by a low base, healthcare vertical continued its strong performance throughout the year.

EBIT margins expanded ~20bps QoQ, in-line with expectations. Utilisation dip on account of strong headcount addition, lower margin revenue from acquired captives and strong increase in other expenses seem to be the key margin headwinds. Continued restrictions on travel and offshorisation could have been the key tailwinds.

- Sharp INR depreciation to cushion near-term margin headwinds. On expected lines, deal win TCV (US$9.2n) remained healthy and the management reiterated double-digit growth outlook for FY22. Given the good pace of vaccination in core markets like US / UK, potential resumption of costs related to marketing events / onsite travel (in H2FY22) is a key thing to watch out for. As we rebase our exchange rate estimates (now INR / US$ = 75 / 76 for FY22 / FY23E), FY22E EPS witnesses ~5% upgrade even as FY23E EPS remains largely stable. We downgrade the stock to HOLD (from ADD earlier) with an unchanged TP of Rs3,350 (implying 30x FY23E EPS).

Shares of TATA CONSULTANCY SERVICES LTD. was last trading in BSE at Rs.3241.45 as compared to the previous close of Rs. 3322.2. The total number of shares traded during the day was 149202 in over 10714 trades.

The stock hit an intraday high of Rs. 3343.9 and intraday low of 3217.75. The net turnover during the day was Rs. 488565310.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Dabur India: REDUCE - Q4FY21 Result Update - YES Securities

Maintain BUY on CreditAccess Grameen - Accelerated write-offs dents earnings - HDFC Securities

Sundram Fasteners Q4 Results Review - HDFC Securities

SRF - Specialty Chemicals continues to shine! - HDFC Securities

Realtors welcome RBI latest stance, expect relief initiatives in next announcement

CreditAccess Grameen - Q4FY21 Result Update - ICICI Securities

JM Financial - Exits FY21 with well contained stress pool; sequential AUM uptick encouraging - ICICI Securities

Hero MotoCorp - Margins remain resilient - ICICI Securities

CEAT - Margin pressures likely to intensify - ICICI Securities

SRF Limited - FY22E growth capped on higher plants utilisation - ICICI Securities

I-direct Instinct - Automotive Axles - ICICI Direct

Quant Pick - Axis Bank - ICICI Direct

Gladiator Stocks - Caplin Point Laboratories - ICICI Direct

Q4FY21 Result Update - Coforge Ltd - ICICI Direct

Tata Consumer Products - Q4FY21 First Cut - ICICI Direct

Coforge Ltd - Q4FY21 Result Update - YES Securities

CreditAccess Grameen - Q4FY21 Result Update - YES Securities

Blue Star - Q4 FY21 first cut - Inline performance - YES Securities

Tata Consumer - 4QFY21 results first cut - YES Securities

Tata Consumer 4QFY21 results first cut - YES Securities

Maintain BUY on CDSL - Strong growth momentum - HDFC Securities

Maintain ADD on L&T Infotech - Steady progression - HDFC Securities

Blue Dart Express - Q4FY21 - The bulge continues - ICICI Securities

Tata Steel - FY22E Net Debt/EBITDA at <1x - ICICI Securities

Larsen & Toubro Infotech - Consistency continues! - ICICI Securities

CEAT - Decent quarter; new capex likely to curtail FCF - ICICI Securities

Q4FY21 Result Update - Alembic Pharma - ICICI Direct

Gladiator Stocks - Cadila Healthcare - ICICI Direct

Q4FY21 Result Update - Larsen & Toubro Infotech - ICICI Direct

RBI Action Update - May 2021 - ICICI Direct

Quant Pick - Aurobindo Pharma - ICICI Direct

Q4FY21 Result Update - Greaves Cotton - ICICI Direct

Adani Total Gas Ltd - Q4FY21 Result Update - YES Securities

L&T Infotech - Q4FY21 Result Update - YES Securities

Bluedart Express - Q4 FY21 first cut - Miss on topline; Profitability improves - YES Securities

Views on the announcement by RBI Governor - Ms. Bekxy Kuriakose, Head - Fixed Income, Principal Asset Management

Views from experts on RBI announcement - May 5, 2021

Maintain REDUCE on RBL Bank - Elevated retail slippages continue - HDFC Securities

Resolution 2.0 measure by RBI to provide relief to real estate linked SME stakeholders

Godrej Properties - Robust quarter; positives fairly priced in - HDFC Securities

RBI Relief 2.0 - May 2021 - Acuité Ratings & Research

MDF Industry - Countervailing duty on MDF recommended; imports may get hit structurally - ICICI Securities

Home First Finance Company - Core earnings steady; profitability buoyed by securitisation income - ICICI Securities

RBL Bank - Modest return profile in the interim; transitioning underway - ICICI Securities

Alembic Pharmaceuticals - US continues to be under pressure - ICICI Securities

Q4FY21 Result Update - SBI Life Insurance - ICICI Direct

Q1CY21 Result Update - Varun Beverages - ICICI Direct

RBL Bank: Views from leading research houses on Q4FY21 results

Q4FY21 Result Update - Supreme Industries - ICICI Direct

Q4FY21 Result Update - Tata Chemicals - ICICI Direct


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020